SunTrust Robinson Reaffirms Their Buy Rating on Healthequity (HQY)

By Jason Carr

In a report released today, Sandy Draper from SunTrust Robinson maintained a Buy rating on Healthequity (HQYResearch Report), with a price target of $55.00. The company’s shares closed last Monday at $41.29, close to its 52-week low of $36.48.

According to, Draper is a 5-star analyst with an average return of 11.6% and a 62.7% success rate. Draper covers the Technology sector, focusing on stocks such as Veeva Systems, Allscripts, and Inovalon.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Healthequity with a $67.63 average price target, a 65.3% upside from current levels. In a report issued on March 11, Wells Fargo also maintained a Buy rating on the stock with a $71.00 price target.

See today’s analyst top recommended stocks >>

Based on Healthequity’s latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $190K. In comparison, last year the company had a net profit of $13.12 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HealthEquity, Inc. provides range of solutions for managing health care accounts. The firm’s offers its solutions for employers, health planbs, brokers, consultants and financial advisors.